948551-64-2

Upstream product

• 3901-07-3 3-(4-methoxy-phenyl)acrylic acid methyl ester 
• 1774-47-6 trimethylsulfoxonium iodide 
• 186581-53-3 diazomethane 
• 6832-16-2 methyl diazoacetate 

Downstream Products

• 92016-94-9 trans-2-(4-methoxyphenyl)cyclopropanecarboxylic acid 
• 5087-21-8 (1R,2R)-2-(4-methoxyphenyl)cyclopropanecarboxylic acid 
• 114095-59-9 (1S*, 2S*)-2-((4-methoxyphenyl)cyclopropyl)methanol 
• 114095-59-9 (2-(4-methoxyphenyl)cyclopropyl)methanol 
• 220349-83-7 (1R,2S)-2-(4-methoxyphenyl)cyclopropanamine 
• 1314323-95-9 (1R,2S)-tert-butyl 2-(4-methoxyphenyl)cyclopropylcarbamate 

Relevant academic research and scientific papers

Donor-Acceptor Bicyclopropyls as 1,6-Zwitterionic Intermediates: Synthesis and Reactions with 4-Phenyl-1,2,4-triazoline-3,5-dione and Terminal Acetylenes

The bicyclopropyl system activated by incorporation of donor and acceptor groups in the presence of Lewis acids was used as a synthetic equivalent of 1,6-zwitterions. Opening of both cyclopropane rings in 2′-aryl-1,1′-bicyclopropyl-2,2-dicarboxylates (D-A bicyclopropyl, ABCDs) in the presence of GaI3 + Bu4N+GaI4- results in 5-iodo-5-arylpent-2-enylmalonates as products of HI formal 1,6-addition to the bicyclopropyl system. The use of GaCl3 or GaBr3 as a Lewis acid and terminal aryl or alkyl acetylenes as 1,6-zwitterion interceptors allows the alkyl substituent to be grown to give the corresponding acyclic 7-chloro(bromo)-hepta-2,6-dienylmalonates. The reaction of ABCDs with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) catalyzed by Yb(OTf)3 also results in the opening of both cyclopropane rings. The reaction products are tetrahydropyridazine derivatives - (7,9-dioxo-1,6,8-triazabicyclo[4.3.0]non-3-en-2-ylmethyl)malonates - containing one more PTAD moiety in the malonyl group.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS

Described herein are methods of treating Parkinson's disease using arylcyclopropylamine compounds.

Synthesis and anticancer activity evaluation of 2(4-alkoxyphenyl)cyclopropyl hydrazides and triazolo phthalazines

A series of new 2(4-alkoxyphenyl)cyclopropyl hydrazide- and triazolo-derivatives were synthesized starting from 4-hydroxycinnamic acid (1) in a clean, mild, efficient and straightforward synthetic protocol. These compounds consisting of different alkoxy substitution, phenylcyclopropyl backbone and different heterocyclic groups were evaluated for in vitro anticancer activity against 4 cell lines displaying certain levels of resistance to pro-apoptotic stimuli and 2 cell lines sensitive to pro-apoptotic compounds. Compounds 7f and 8e were most active and displaying moderate in vitro cytostatic effect through different mechanisms. Significantly, chemically modified derivatives could be obtained in order to develop novel types of compounds aiming to combat apoptosis-resistant cancers, for example, those cancers associated with dismal prognoses.